UroGen Pharma
URGN
UroGen Pharma (URGN) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Maintained | Buy | $75.00 from $45.00 | Aug 6, 2026 |
| Guggenheim | Maintained | Buy | $58.00 from $42.00 | Aug 6, 2026 |
| TD Cowen | Maintained | Buy | $60.00 from $50.00 | Aug 5, 2026 |
| Guggenheim | Maintained | Buy | $42.00 from $32.00 | Jul 21, 2026 |
| Oppenheimer | Maintained | Outperform → Outperformer | $50.00 from $40.00 | Jul 16, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $45.00 | Jun 3, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $45.00 | May 18, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $45.00 from $40.00 | May 11, 2026 |
| Oppenheimer | Maintained | Outperform | $40.00 from $34.00 | May 7, 2026 |
| D. Boral Capital | Maintained | Buy | $33.00 | Mar 31, 2026 |
| D. Boral Capital | Maintained | Buy | $33.00 | Mar 2, 2026 |
| D. Boral Capital | Maintained | Buy | $33.00 | Jan 23, 2026 |
| D. Boral Capital | Maintained | Buy | $33.00 | Jan 5, 2026 |
| D. Boral Capital | Maintained | Buy | $25.00 | Oct 27, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $40.00 | Oct 27, 2025 |
| D. Boral Capital | Maintained | Buy | $25.00 | Oct 3, 2025 |
| Piper Sandler | Initiated Coverage | Overweight | $36.00 | Aug 19, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $40.00 from $50.00 | Aug 11, 2025 |
| D. Boral Capital | Maintained | Buy | $25.00 | Aug 7, 2025 |
| D. Boral Capital | Maintained | Buy | $25.00 | Aug 5, 2025 |
Frequently asked questions
What is the latest analyst rating on URGN?
On Aug 6, 2026, HC Wainwright & Co. maintained UroGen Pharma at Buy with a price target of $75.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.